The rise in valuations of Big Biotech is due in large part to the fact that they're seen as affordable acquisition candidates for Big Pharmas in search of late-stage products. The plethora of early-stage biotech consolidation is, in contrast, generally a choice of last resort for otherwise unfinanceable companies who also can't sign worthwhile pharma deals. But the attention on late-stage programs offers opportunities for companies, like Pfizer, to strike platform technology deals which transfer technology, royalty free, from biotech to drug firm. The deals aren't cheap but these structures, impossible when platform deals were popular, allow Pfizer much greater research freedom.
The money in the pharmaceutical industry continues to chase a
single quarry: certainty.
In an economy which grows almost despite itself, investors don't need to look to pharmaceutical companies for steady earnings growth....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
